Figure S8 from Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor Efficacy
Abstract
Immune cell phenotyping of CT26/HAS tumours at early time points and MC38/OVA tumours at 14d post-dose.
Fields of Study & Subjects
Proteoglycans and glycosaminoglycans research
Cancer Immunotherapy and Biomarkers
Immunotherapy and Immune Responses
Publication details
- Publication date
- 4 March 2026
- Language
- EN